Background: The efficacy of cannabinoids in neuropathic pain is still unknown. Pain management is critical for patients because it creates a negative impact on the quality of life of patients.Objective: This study aims to demonstrate the evidence towards the effectiveness of cannabinoid drugs in controlling oncological neuropathic pain, by evaluating the available literature.Methodology: A systematic review of literature was conducted including experimental, observational studies and systematic reviews over a period of 15 years All studies since 2000 with Oxford evidence scale as IB were included.Results: Four studies met criteria for its inclusion, but the evidence is low and does not allow to recommend or discard cannabinoids as adjunctive therapy in cancer control neuropathic pain. The combination of THC / CBD (Sativex) appears to be safe for its use, and is not associated with deaths reported, however the presentation of adverse gastrointestinal and neurological level events could increase the risk of drug interactions and have a negative impact on the quality of life of cancer patients.Conclusions: There is not enough literature and evidence is not sufficient to recommend or discard the use of cannabinoids in neuropathic cancer pain. Future studies should be conducted to analyze the benefit of these drugs. Although ethically and socially there is resistance to the use of cannabinoids, there is currently a great political discussion in the world and in Colombia for acceptance as therapy in pain control.